Boston gets $169 million from stent patent ruling
This article was originally published in Clinica
Boston Scientific has won a patent infringement arbitration with Medtronic and has been awarded $169 million in damages, as well as costs and injunction fees. There is also a permanent injunction against Medtronic selling its rapid exchange stent delivery systems and balloon dilatation catheters in the US. The decision by the arbitration panel is binding.